Microchip battles retinitis pigmentosa

Article

Optobionics Corporation has announced positive interim results from a pilot clinical trial of its Artificial Silicon Retina (ASR) device, a treatment for retinitis pigmentosa.

Optobionics Corporation has announced positive interim results from a pilot clinical trial of its Artificial Silicon Retina (ASR) device, a treatment for retinitis pigmentosa.

A total of 20 patients were enrolled in a study to assess safety and to develop effective vision measures under an Investigational Device Exemption application approved by the FDA. At twelve months follow-up, of the ten subjects suffering with retinitits pigementosa, 40% attained a ten-letter improvement in visual acuity compared with a loss of vision for the untreated patients. No patient showed signs of implant rejection, infection, inflammation, erosion or retinal detachment related to the implanted device.

The ASR is a microchip designed to stimulate damaged retinal cells, allowing them to send visual signals again to the brain. As well as being a possible treatment option for retinitis pigmentosa, the manufacturers believe it could also be used to help treat age-related macular degeneration.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.